Tecentriq Alternatives Compared
| Tecentriq (atezolizumab) | Nivolumab | Pembrolizumab |
|
|---|
| Tecentriq (atezolizumab) | Nivolumab | Pembrolizumab |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Small Cell Lung Cancer, Non Small Cell Lung Cancer, Hepatocellular Carcinoma, Alveolar Soft Part Sarcoma, Melanoma. Tecentriq may also be used for purposes not listed in this medication guide. View more |
Prescription only
Prescribed for Head and Neck Cancer, Esophageal Carcinoma, Hepatocellular Carcinoma, Colorectal Cancer, Gastric Cancer, Hodgkin's Lymphoma, Malignant Pleural Mesothelioma, Melanoma, Melanoma -... View more |
Prescription only
Prescribed for Bladder Cancer, Cervical Cancer, Breast Cancer, Biliary Tract Tumor, Colorectal Cancer, Endometrial Cancer, Esophageal Carcinoma, Gastric Cancer, Head and Neck Cancer, Hepatocellular... View more |
Related suggestions Popular comparisons
|
|||||||
| More about Tecentriq (atezolizumab) | More about Nivolumab | More about Pembrolizumab | ||||||||
| Ratings & Reviews | ||||||||||
|
Tecentriq has an average rating of 0.0 out of 10 from a total of 1 ratings on Drugs.com. |
Nivolumab has an average rating of 5.6 out of 10 from a total of 130 ratings on Drugs.com. 49% of reviewers reported a positive effect, while 44% reported a negative effect. |
Pembrolizumab has an average rating of 5.1 out of 10 from a total of 267 ratings on Drugs.com. 42% of reviewers reported a positive effect, while 47% reported a negative effect. |
||||||||
| Drug Class | ||||||||||
| Side Effects | ||||||||||
| Generic Availability | ||||||||||
|
N/A |
N/A |
N/A |
||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||
View all Tecentriq prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||
| Dosage Forms Available | ||||||||||
|
N/A |
N/A |
||||||||
| Brand Names | ||||||||||
|
N/A |
Opdivo | Keytruda | ||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||
|
648 hours |
640.8 hours |
624 hours |
||||||||
| CSA Schedule ** View glossary of terms | ||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | ||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
||||||||
| Drug Interactions | ||||||||||
|
A total of 439 drugs are known to interact with Tecentriq:
|
A total of 403 drugs are known to interact with Nivolumab:
|
A total of 403 drugs are known to interact with Pembrolizumab:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||
| Disease Interactions | ||||||||||
| First Approval Date | ||||||||||
|
May 18, 2016 |
December 22, 2014 |
N/A |
||||||||
| WADA Class View World Anti-Doping Agency classifications. | ||||||||||
|
N/A |
N/A |
N/A |
||||||||
| More Information | ||||||||||
| Patient resources | ||||||||||
| Professional Resources | ||||||||||
| Related Treatment Guide | ||||||||||
|
||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.